OncoMatch/Clinical Trials/NCT06812728
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
Is NCT06812728 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including mFOLFIRINOX and mFolfox6 for rectum cancer.
Treatment: mFOLFIRINOX · mFolfox6 — A phase II clinical trial compared standard TNT (mFolfox6 and CRT) with preoperative chemoradiotherapy (CRT) with neoadjuvant chemotherapy (CT) containing mFolfirinox in patients with locally advanced rectal cancer.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage CT3 WITH RISK OF LOCAL RECURRENCE, N POSITIVE (clinical TNM)
Excluded: Stage METASTATIC DISEASE
Stages cT3 with risk of local recurrence, cT4, or N positive, M0 and for which a multidisciplinary meeting recommend TNT.
Performance status
WHO/ECOG 0–1
Prior therapy
Cannot have received: radiotherapy
No prior radiotherapy of the pelvis for any reason
Cannot have received: chemotherapy
no previous CT
Lab requirements
Blood counts
Adequate hematologic function.
Liver function
Adequate hepatic function.
Cardiac function
No heart failure or coronary heart disease symptoms (even controlled). No history of angina pectoris or myocardial infarction.
No heart failure or coronary heart disease symptoms (even controlled). No history of angina pectoris or myocardial infarction. Adequate hematologic function. Adequate hepatic function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify